H. Lundbeck A/s

Synaptic Pharmaceutical Corporation

James A Bonini

Beth E Borowsky

Christophe P G Gerald

Kenneth A Jones

Douglas A Craig

Nika Adham

Noel Boyle

Thelma O Thompson

Kristine L Ogozalek

Gabriel S Lerman

Yong Quan

This invention provides isolated nucleic acids encoding mammalian SNORF25 receptors, purified mammalian SNORF25 receptors, vectors comprising nucleic acid encoding mammalian SNORF25 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF25 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF25 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF25 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF25 receptors, methods of isolating mammalian SNORF25 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF25 receptors, as well as methods of determining binding of compounds to mammalian SNORF25 receptors, methods of identifying agonists and antagonists of SNORF25 receptors, and agonists and antagonists so identified.

DNA encoding SNORF25 receptor

This invention provides isolated nucleic acids encoding mammalian NPFF receptors, purified mammalian NPFF receptors, vectors comprising nucleic acid encoding mammalian NPFF receptors, cells comprising such vectors, antibodies directed to mammalian NPFF receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian NPFF receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian NPFF receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian NPFF receptors, methods of isolating mammalian NPFF receptors, methods of treating an abnormality that is linked to the activity of the mammalian NPFF receptors, as well as methods of determining binding of compounds to mammalian NPFF receptors, methods of identifying agonists and antagonists of NPFF receptors, and agonists and antagonists so identified.

DNA encoding mammalian neuropeptide FF (NPFF) receptors and uses thereof

Methods of identifying agonists and antagonists of mammalian NPFF receptor

This invention provides isolated nucleic acids encoding mammalian SNORF62 and SNORF72 receptors, purified mammalian SNORF62 and SNORF72 receptors, vectors comprising nucleic acid encoding mammalian SNORF62 and SNORF72 receptors, cells comprising such vectors, antibodies directed to mammalian SNORF62 and SNORF72 receptors, nucleic acid probes useful for detecting nucleic acid encoding mammalian SNORF62 and SNORF72 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian SNORF62 and SNORF72 receptors, transgenic, nonhuman animals which express DNA encoding normal or mutant mammalian SNORF62 and SNORF72 receptors, methods of isolating mammalian SNORF62 and SNORF72 receptors, methods of treating an abnormality that is linked to the activity of the mammalian SNORF62 and SNORF72 receptors, as well as methods of determining binding of compounds to mammalian SNORF62 and SNORF72 receptors, methods of identifying agonists and antagonists of SNORF62 and SNORF72 receptors, and agonists and antagonists so identified. This invention also provides methods of treating an abnormality that is linked to the activity of a mammalian NMU receptor, as well as methods of determining binding of compounds to mammalian NMU receptors, methods of identifying agonists and antagonists of NMU receptors, and agonists and antagonists so identified.

Processes for obtaining compounds employing SNORF72 receptors

Methods of identifying compounds that bind to SNORF25 receptors

DNA encoding mammalian neuropeptides FF (NPFF) receptors and uses thereof

This invention provides a recombinant nucleic acid comprising a nucleic acid encoding a mammalian SNORF1 receptor, wherein the mammalian receptor-encoding nucleic acid hybridizes under high stringency conditions to (a) a nucleic acid encoding a human SNORF1 receptor and having a sequence identical to the sequence of the human SNORF1 receptor-encoding nucleic acid contained in plasmid pEXJ-hSNORF1-f (ATCC Accession No. 203898) or (b) a nucleic acid encoding a rat SNORF1 receptor and having a sequence identical to the sequence of the rat SNORF1 receptor-encoding nucleic acid contained in plasmid pcDNA3.1-rSNORF1-f (ATCC Accession No. 203897). This invention further provides a recombinant nucleic acid comprising a nucleic acid encoding a human SNORF1 receptor, wherein the human SNORF1 receptor comprises an amino acid sequence identical to the sequence of the human SNORF1 receptor encoded by the shortest open reading frame indicated in FIGS. 1A-1B (Seq. I.D. No. 1). This invention also provides a recombinant nucleic acid comprising a nucleic acid encoding a rat SNORF1 receptor, wherein the rat SNORF1 receptor comprises an amino acid sequence identical to the sequence of the rat SNORF1 receptor encoded by the shortest open reading frame indicated in FIGS. 3A-3B (Seq. I.D. No. 3).

DNA encoding SNORF1 receptor

Growing community of inventors

Oakland, NJ, United States of America

James A Bonini